Evidence-Based Medical News

Mode

All Infectious Disease Oncology Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Gastroenterology Primary Care & Family Medicine Nutrition & Obesity Medicine OB/GYN & Women's Health Orthopedics & Sports Medicine Genetics & Precision Medicine Radiology & Imaging Pulmonology & Critical Care Anesthesiology & Pain Medicine Physical Medicine & Rehab Nephrology Hematology Dermatology Urology Emergency Medicine Ophthalmology Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Text Size

Log in / Sign up

Lung Cancer

11 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Lung Cancer

343 trials tracked for Lung Cancer: 37 in phase 3 or 4 and 13 with published results. The most-cited published study has 1650 citations.

343Trials tracked

37Phase 3 & 4

0Recruiting

13With published results

Phase distribution

Phase 4 4 Phase 3 33 Phase 2 177 Phase 1 14 Other / NA 115

Phase 3 Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases Completed · 1,650 cited
Phase 3 ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants Completed · 970 cited
Phase 3 High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery Completed · 572 cited
Phase 3 Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC Completed · 392 cited
Phase 3 An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy Completed · 264 cited
Phase 3 Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014) Completed · 220 cited

Show 44 more trials

Phase 3 Surgery With or Without Internal Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer Completed · 114 cited
Phase 4 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed · 112 cited
Phase 3 Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery Completed · 107 cited
Phase 3 Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Completed · 76 cited
Phase 4 An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers Completed · 71 cited
Phase 3 PROStep: A Feasibility Trial Using PROs and Step Data to Monitor Patients With Lung and GI Cancers Completed · 16 cited
Phase 3 Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC Completed · 10 cited
Phase 4 Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly Completed
Phase 4 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed
Phase 3 Selenium in Preventing Tumor Growth in Patients With Previously Resected Stage I Non-small Cell Lung Cancer Completed
Phase 3 Iressa Follow-up Trial Completed
Phase 3 Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer Completed
Phase 3 A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks Completed
Phase 3 ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor Targeting Completed
Phase 3 T790M Plasma Testing Methodology Comparison and Clinical Validation Completed
Phase 3 A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia Completed
Phase 3 A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer Completed
Phase 3 Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer Completed
Phase 3 Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003) Completed
Phase 3 Bintrafusp Alfa Program Rollover Study Completed
Phase 3 Evaluation of the Bio-Seal Biopsy Track Plug Completed
Phase 3 PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer Completed
Phase 3 National Lung Screening Trial (NLST) Screening Completed
Phase 3 Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients Completed
Phase 3 Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer Completed
Phase 3 ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer Completed
Phase 3 Melatonin Versus Placebo and the Effect on Appetite in Advanced Cancer Patients Completed
Phase 3 S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer Completed
Phase 3 Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer Completed
Phase 3 Cediranib, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed
Phase 3 Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer Completed
Phase 2 Proton Radiotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC) Completed
Phase 2 Study of Arsenic Trioxide in Small Cell Lung Cancer Completed
Phase 2 Percutaneous Image Guided Video-Assisted Thoracic Surgery (VATS) Resection of Lung Lesions Completed
Phase 2 BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC Completed
Phase 2 Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer Completed
Phase 2 Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer Completed
Phase 2 Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer Completed
Phase 2 Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Completed
Phase 2 Study of Vinorelbine and Cisplatin as Induction Therapy With Radiotherapy in Patients With Unresectable NSCLC Completed
Phase 2 Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer Completed
Phase 2 A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) Completed
Phase 2 Minocycline Study in Non Small Cell Lung Cancer (NSCLC) Patients for Chemoradiation Therapy Completed
Phase 2 BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery Completed

Showing the 50 most-cited and recently-updated of 343 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

Questions about Lung Cancer

How well does osimertinib work for lung cancer patients who have active brain metastasis?

Osimertinib is effective for EGFR-mutated NSCLC patients with active brain metastases, with real-world data showing median progression-free survival of 12.4 months and intracranial responses, though resistance can develop.

Full answer →

Which method is best for placing fiducial markers before radiation for lung cancer?

Endobronchial access has the lowest inaccurate placement rate and low complication risk, making it a strong choice for fiducial marker insertion before lung cancer radiation.

Full answer →

Can a high neutrophil-to-lymphocyte ratio predict if lung cancer will spread to the brain?

Yes, a high neutrophil-to-lymphocyte ratio (NLR) is an independent risk factor for brain metastasis in lung cancer, according to a meta-analysis of 14 studies.

Full answer →

What are the risks of brain metastasis in patients diagnosed with lung cancer?

Brain metastases are common in lung cancer, especially small cell (15% at diagnosis) and non-small cell types, with elevated neutrophil-to-lymphocyte ratio as a risk factor; targeted therapies like osimertinib show high intracranial response rates.

Full answer →